The protective effect of BCG against tuberculosis (TB) estimated in randomized controlled trials and observational studies ranges from negative to close to a 100%. One of the many explanations offered for this is that different immunological mechanisms may be associated with protective effect against different forms and sites of disease.
In this investigation, we recalculated vaccine protective effect separately for pulmonary disease and for meningeal/miliary disease in randomized controlled trials and case-control studies, tested for heterogeneity in site-specific estimates of protective effect and calculated a summary measure when appropriate.
We found protective effect against pulmonary disease to be heterogenous to a statistically significant degree, and thus we did not calculate a summary measure of protection.
Mots-clés Pascal : Méningite, Tuberculose miliaire, Mycobactériose, Bactériose, Infection, BCG, Vaccination, Prévention, Efficacité, Métaanalyse, Essai clinique, Homme, Système nerveux pathologie, Système nerveux central pathologie
Mots-clés Pascal anglais : Meningitis, Miliary tuberculosis, Mycobacterial infection, Bacteriosis, Infection, BCG, Vaccination, Prevention, Efficiency, Metaanalysis, Clinical trial, Human, Nervous system diseases, Central nervous system disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0148677
Code Inist : 002B05B02O. Création : 199406.